Milan

• A Phase 3 Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting
  2022-502629-16-00 5 2024-07-10 Hemolytic Disease of the Fetus and Newborn (HDFN)
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients with Advanced … Recruiting
  2023-508178-27-00 9 2024-07-10 Participants with Advanced KRASG12C-Mutated Solid Tumors
• Phase I/II, open-label, multi-center study to evaluate the safety and efficacy of glyco-humanized polyclonal antibody directed against tumor … Recruiting
  2023-509648-88-00 9 2024-07-09 Peripheral T cells lymphoma (PTCL)
• A study evaluating the safety and efficacy of an experimental drug for chronic lung disease against normally prescribed care in extremely pr … Recruiting
  2024-515914-41-00 4 2024-07-05 Chronic Lung Disease
• N-PLUS Recruiting
  2022-502559-69-01 4 2024-07-04 advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIGO classifi
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C … Recruiting
  2023-507407-59-00 5 2024-07-04 Chronic Obstructive Pulmonary Disease (COPD)
• A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i … Recruiting
  2023-508204-38-00 5 2024-07-02 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617 … Recruiting
  2022-502956-29-00 5 2024-07-01 Oligometastatic prostate cancer (OMPC)
• Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism Recruiting
  2024-511959-18-01 5 2024-07-01 Acute Pulmonary Embolism
• Study of INBRX-109 in Patients with Advanced Solid Tumors, Including Sarcomas. Recruiting
  2023-508139-29-00 7 2024-06-26 Advanced or metastatic solid tumors
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can … Recruiting
  2023-507914-28-00 10 2024-06-19 Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
• A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or … Recruiting
  2023-504514-29-00 1 2024-06-18 Gastroesophageal Junction (GEJ) Adenocarcinoma
• A study to learn if rozanolixizumab is safe, how it moves through the body, and if it works in children with myasthenia gravis Recruiting
  2022-502074-16-00 10 2024-06-14 Generalized Myasthenia Gravis
• Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting
  2023-509551-14-00 5 2024-06-12 Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
• A clinical study to test the effect of niraparib and immunotherapy, for patients with small cell lung cancer (SCLC) that is positive for SLF … Recruiting
  2022-502092-33-00 4 2024-05-31 Extensive-disease small cell lung cancer and high SLFN11-expression
• Anti-viral action against Type 1 diabetes autoimmunity GPPAD-05-AVAnT1A Recruiting
  2023-507348-35-00 6 2024-05-30 Risk for Type 1 Diabetes
• A Phase 3 study of Dostarlimab as Sequential Therapy after Chemoradiation compared to placebo in adult participants with Locally Advanced Un … Recruiting
  2023-508613-17-00 5 2024-05-29 Neoplasms, Head and Neck
• Phase 1, First-in-Human Study to Assess the Safety, Tolerability and Anti-tumor Activity of CDR404 in HLA-A*02:01 Participants with MAGE-A4 … Recruiting
  2023-508808-38-00 1 2024-05-29 Solid tumors
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting
  2023-504251-27-00 7 2024-05-27 Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mut
• A Phase 1b/2 Study of BGB-11417 as Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, Dexamethasone plus Daratumum … Recruiting
  2023-507751-30-00 9 2024-05-27 relapsed or refractory multiple myeloma
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION) Recruiting
  2023-505043-39-00 5 2024-05-24 Duchenne Muscular Dystrophy

Showing 937–960 of 2,361 trials